These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15468165

  • 1. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
    Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodríguez-Henche N, Chiloeches A, Prieto JC, Carmena MJ.
    Prostate; 2005 Apr 01; 63(1):44-55. PubMed ID: 15468165
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y, Wolff DW, Lin MF, Tu Y.
    Mol Pharmacol; 2007 Jul 01; 72(1):73-85. PubMed ID: 17430995
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1.
    Fernández M, Sánchez-Franco F, Palacios N, Sánchez I, Cacicedo L.
    J Mol Endocrinol; 2005 Jun 01; 34(3):699-712. PubMed ID: 15956341
    [Abstract] [Full Text] [Related]

  • 6. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.
    Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748
    [Abstract] [Full Text] [Related]

  • 7. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
    Iacopino F, Lama G, Angelucci C, Sica G.
    Int J Oncol; 2006 Jul 17; 29(1):237-47. PubMed ID: 16773205
    [Abstract] [Full Text] [Related]

  • 8. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME, Deeble PD, Lakhani S, Parsons SJ.
    Cancer Res; 1999 Aug 01; 59(15):3821-30. PubMed ID: 10447001
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
    Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B.
    J Endocrinol; 2005 Jun 01; 185(3):577-92. PubMed ID: 15930183
    [Abstract] [Full Text] [Related]

  • 12. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
    Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.
    Prostate; 2009 May 15; 69(7):774-86. PubMed ID: 19189304
    [Abstract] [Full Text] [Related]

  • 13. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
    Xie S, Lin HK, Ni J, Yang L, Wang L, di Sant'Agnese PA, Chang C.
    Prostate; 2004 Jun 15; 60(1):61-7. PubMed ID: 15129430
    [Abstract] [Full Text] [Related]

  • 14. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
    Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.
    Mol Cell Endocrinol; 2007 May 30; 270(1-2):8-16. PubMed ID: 17434257
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH-SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway.
    Alleaume C, Eychène A, Harnois T, Bourmeyster N, Constantin B, Caigneaux E, Muller JM, Philippe M.
    Exp Cell Res; 2004 Oct 01; 299(2):511-24. PubMed ID: 15350548
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.
    Hokari R, Lee H, Crawley SC, Yang SC, Gum JR, Miura S, Kim YS.
    Am J Physiol Gastrointest Liver Physiol; 2005 Nov 15; 289(5):G949-59. PubMed ID: 16227528
    [Abstract] [Full Text] [Related]

  • 18. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression.
    Yang W, Chen Y, Zhang Y, Wang X, Yang N, Zhu D.
    Cancer Res; 2006 Feb 01; 66(3):1320-6. PubMed ID: 16452185
    [Abstract] [Full Text] [Related]

  • 19. Melanocortin 5 receptor activates ERK1/2 through a PI3K-regulated signaling mechanism.
    Rodrigues AR, Pignatelli D, Almeida H, Gouveia AM.
    Mol Cell Endocrinol; 2009 May 06; 303(1-2):74-81. PubMed ID: 19428994
    [Abstract] [Full Text] [Related]

  • 20. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.
    Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC, Carmena MJ.
    Regul Pept; 2004 Jun 15; 119(1-2):69-75. PubMed ID: 15093699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.